Mirum Pharmaceuticals Inc
For the period ended Dec 31, 2024. Filed Feb 26, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 26, 2025
MIRM$93.18-0.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
| Year Ended December 31, | |||
|---|---|---|---|
| 2024 | 2023 | 2022 | |
| Revenue: | |||
| Product sales, net | $336,409 | $178,874 | $75,062 |
| License and other revenue | 479 | 7,500 | 2,000 |
| Total revenue | 336,888 | 186,374 | 77,062 |
| Operating expenses: | |||
| Cost of sales | 81,643 | 47,039 | 12,374 |
| Research and development | 140,630 | 102,609 | 106,842 |
| Selling, general and administrative | 202,221 | 145,880 | 89,066 |
| Total operating expenses | 424,494 | 295,528 | 208,282 |
| Loss from operations | (87,606) | (109,154) | (131,220) |
| Other income (expense): | |||
| Interest income | 13,792 | 13,735 | 3,857 |
| Interest expense | (14,311) | (15,105) | (15,979) |
| Change in fair value of derivative liability | — | — | 906 |
| Loss from termination of revenue interest purchase agreement | — | (49,076) | — |
| Other income (expense), net | 1,213 | (2,824) | 365 |
| Loss before provision for income taxes | (86,912) | (162,424) | (142,071) |
| Provision for (benefit from) income taxes | 1,030 | 991 | (6,406) |
| Net loss | $(87,942) | $(163,415) | $(135,665) |
| Net loss per share: | |||
| Basic | $(1.85) | $(4.00) | $(4.01) |
| Diluted | $(1.85) | $(4.00) | $(4.02) |
| Weighted-average shares of common stock outstanding | |||
| Basic | 47,522,594 | 40,885,124 | 33,839,072 |
| Diluted | 47,522,594 | 40,885,124 | 33,982,493 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.